Technical Analysis for NNVC - NanoViricides, Inc.

Grade Last Price % Change Price Change
F 1.15 -4.17% -0.05
NNVC closed down 4.17 percent on Monday, March 18, 2024, on 36 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Flat Flat

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -4.17%
Oversold Stochastic Weakness -4.17%
Crossed Above 50 DMA Bullish -1.71%
180 Bullish Setup Bullish Swing Setup -1.71%
Pocket Pivot Bullish Swing Setup -1.71%
NR7 Range Contraction -1.71%
Narrow Range Bar Range Contraction -1.71%
Gapped Up Strength -1.71%

   Recent Intraday Alerts

Alert Time
Fell Below Previous Day's Low about 11 hours ago
Down 2 % about 11 hours ago
Down 1% about 15 hours ago
20 DMA Resistance 4 days ago
60 Minute Opening Range Breakout 4 days ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

NanoViricides, Inc. Description

NanoViricides, Inc. a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at advanced pre-clinical stage, which include two FluCide drugs comprising NV-INF-2, an oral anti-influenza drug and NV-INF-1, a injectable anti-influenza drug for novel strain of H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could enable a functional cure for HIV/AIDS; HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes lesions; Nanoviricide anti-viral eye drops against external eye viral infections; and DengueCide, a treatment against Dengue viruses. It is also developing RabiCide, an anti-rabies nanoviricide; and Nanoviricide for the treatment of various strains of Ebola and Marburg filoviruses. The company has licenses to develop drugs for the treatment of human viral diseases, such as H5N1 (avian flu), human influenza, human immunodeficiency virus (HIV/AIDS), hepatitis B virus, hepatitis C virus, herpes simplex virus, and rabies; and dengue viruses, Japanese encephalitis virus, West Nile virus, viruses causing viral conjunctivitis and ocular herpes, and Ebola/Marburg viruses, as well as viral diseases of the eye comprising epidemic kerato-conjunctivitis and herpes keratitis. NanoViricides, Inc. was founded in 2005 and is based in West Haven, Connecticut.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Medicine Infectious Diseases Eye Infection Coronavirus Influenza Hepatitis B Viruses HIV Hepatitis C Immunodeficiency Hepatitis C Virus Virus Hepatitis B Virus Viral Disease Antiviral Drug HIV/Aids Herpes Rabies Ebola Herpes Simplex Dengue Epidemiology Herpes Simplex Virus Viral Conjunctivitis Viral Infections Genital Herpes Viral Infection

Is NNVC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.0
52 Week Low 1.0
Average Volume 34,184
200-Day Moving Average 1.23
50-Day Moving Average 1.15
20-Day Moving Average 1.22
10-Day Moving Average 1.15
Average True Range 0.07
RSI (14) 45.65
ADX 18.21
+DI 19.82
-DI 16.90
Chandelier Exit (Long, 3 ATRs) 1.18
Chandelier Exit (Short, 3 ATRs) 1.31
Upper Bollinger Bands 1.38
Lower Bollinger Band 1.06
Percent B (%b) 0.28
BandWidth 26.04
MACD Line -0.01
MACD Signal Line 0.00
MACD Histogram -0.011
Fundamentals Value
Market Cap 13.51 Million
Num Shares 11.7 Million
EPS -0.77
Price-to-Earnings (P/E) Ratio -1.49
Price-to-Sales 0.00
Price-to-Book 1.03
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.24
Resistance 3 (R3) 1.25 1.23 1.23
Resistance 2 (R2) 1.23 1.21 1.23 1.22
Resistance 1 (R1) 1.19 1.19 1.18 1.18 1.21
Pivot Point 1.17 1.17 1.17 1.17 1.17
Support 1 (S1) 1.13 1.15 1.12 1.12 1.09
Support 2 (S2) 1.11 1.13 1.11 1.08
Support 3 (S3) 1.07 1.11 1.08
Support 4 (S4) 1.06